Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid

References

• Altin JG, Banwell MG, Coghlan PA, Easton CJ, Nairn MR, Offermann DA. (2006). Synthesis of NTA(3)-DTDA—a chelator–lipid that promotes stable binding of His-tagged proteins to membranes. Aust J Chem, 59, 302–306.
   Web of Science ®Google Scholar
• Arap W, Pasqualini R, Ruoslahti E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279, 377–380.
   PubMed Web of Science ®Google Scholar
• Chang DK, Chiu CY, Kuo SY, Lin WC, Lo A, Wang YP, Li PC, Wu HC. (2009). Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J Biol Chem, 284, 12905–12916.
   PubMed Web of Science ®Google Scholar
• Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, Liu Y, Wu W, Shao X, Mao Y, Wei Y, Chen L. (2010). Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release, 145, 17–25.
   PubMed Web of Science ®Google Scholar
• Eikenberry S. (2009). A tumor cord model for doxorubicin delivery and dose optimization in solid tumors. Theor Biol Med Model, 6, 16.
   PubMed Web of Science ®Google Scholar
• Elbayoumi TA, Torchilin VP. (2007). Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci, 32, 159–168.
   PubMed Web of Science ®Google Scholar
• ElBayoumi TA, Torchilin VP. (2009). Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res, 15, 1973–1980.
   PubMed Web of Science ®Google Scholar
• Faham A, Bennett D, Altin JG. (2009). Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent Ag-specific and anti-tumour immunity. Vaccine, 27, 5846–5854.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Tzemach D, Gorin J, Mak L, Amitay Y, Shmeeda H, Zalipsky S. (2010). Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol, 66, 43–52.
   PubMed Web of Science ®Google Scholar
• Gabizon AA. (1992). Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res, 52, 891–896.
   PubMed Web of Science ®Google Scholar
• Hamzah J, Altin JG, Herringson T, Parish CR, Hämmerling GJ, O’Donoghue H, Ganss R. (2009). Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J Immunol, 183, 1091–1098.
   PubMed Web of Science ®Google Scholar
• Herringson TP, Altin JG. (2009). Convenient targeting of stealth siRNA-lipoplexes to cells with chelator lipid-anchored molecules. J Control Release, 139, 229–238.
   PubMed Web of Science ®Google Scholar
• Herringson TP, Patlolla RR, Altin JG. (2009). Targeting of plasmid DNA-lipoplexes to cells with molecules anchored via a metal chelator lipid. J Gene Med, 11, 1048–1063.
   PubMed Web of Science ®Google Scholar
• Hölig P, Bach M, Völkel T, Nahde T, Hoffmann S, Müller R, Kontermann RE. (2004). Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng Des Sel, 17, 433–441.
   PubMed Web of Science ®Google Scholar
• Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D. (1992). Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res, 52, 6774–6781.
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine, 1, 297–315.
   PubMed Web of Science ®Google Scholar
• Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. (2003). Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell, 4, 393–403.
   PubMed Web of Science ®Google Scholar
• Kuroda K, Miyata K, Fujita F, Koike M, Fujita M, Nomura M, Nakagawa S, Tsutsumi Y, Kawagoe T, Mitsuishi Y, Mayumi T. (2000). Human tumor necrosis factor-alpha mutant RGD-V29 (F4614) shows potent antitumor activity and reduced toxicity against human tumor xenografted nude mice. Cancer Lett, 159, 33–41.
   PubMed Web of Science ®Google Scholar
• Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E. (2002). A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med, 8, 751–755.
   PubMed Web of Science ®Google Scholar
• Laakkonen P, Vuorinen K. (2010). Homing peptides as targeted delivery vehicles. Integr Biol (Camb), 2, 326–337.
   PubMed Web of Science ®Google Scholar
• Laginha KM, Verwoert S, Charrois GJ, Allen TM. (2005). Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res, 11, 6944–6949.
   PubMed Web of Science ®Google Scholar
• Lee RJ, Low PS. (1995). Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta, 1233, 134–144.
   PubMed Web of Science ®Google Scholar
• Li X, Ding L, Xu Y, Wang Y, Ping Q. (2009). Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm, 373, 116–123.
   PubMed Web of Science ®Google Scholar
• Mitra A, Mulholland J, Nan A, McNeill E, Ghandehari H, Line BR. (2005). Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release, 102, 191–201.
   PubMed Web of Science ®Google Scholar
• O’Donnell RT, Martin SM, Ma Y, Zamboni WC, Tuscano JM. (2010). Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD). Invest New Drugs, 28, 260–267.
   PubMed Web of Science ®Google Scholar
• Onthank DC, Liu S, Silva PJ, Barrett JA, Harris TD, Robinson SP, Edwards DS. (2004). 90Y and 111In complexes of a DOTA-conjugated integrin alpha v beta 3 receptor antagonist: different but biologically equivalent. Bioconjug Chem, 15, 235–241.
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. (2002). Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res, 8, 1172–1181.
   PubMed Web of Science ®Google Scholar
• Plosker GL. (2008). Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs, 68, 2535–2551.
   PubMed Web of Science ®Google Scholar
• Siegal T, Horowitz A, Gabizon A. (1995). Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg, 83, 1029–1037.
   PubMed Web of Science ®Google Scholar
• Soundararajan A, Bao A, Phillips WT, Perez R 3rd, Goins BA. (2009). [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol, 36, 515–524.
   PubMed Web of Science ®Google Scholar
• Symons M, Segall JE. (2009). Rac and Rho driving tumor invasion: who’s at the wheel? Genome Biol, 10, 213.
   PubMed Web of Science ®Google Scholar
• Temming K, Schiffelers RM, Molema G, Kok RJ. (2005). RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat, 8, 381–402.
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG. (2005). Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol, 96, 10–18.
   PubMed Web of Science ®Google Scholar
• Udhrain A, Skubitz KM, Northfelt DW. (2007). Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma. Int J Nanomedicine, 2, 345–352.
   PubMed Web of Science ®Google Scholar